FN3K expression in COPD: a potential comorbidity factor for cardiovascular disease

Area of Science:

• Pulmonary Medicine
• Cardiovascular Disease Research
• Biochemistry

Background:

• Chronic obstructive pulmonary disease (COPD) is linked to oxidative stress and cardiovascular disease (CVD) comorbidities.
• Advanced glycation endproducts (AGE) elevate CVD risk and mortality in COPD patients.
• Fructosamine-3-kinase (FN3K) enzyme activity is associated with reduced AGE levels.

Purpose of the Study:

• To investigate FN3K protein distribution and expression in COPD lung tissues and blood.
• To assess the effect of metformin on FN3K and AGE levels in COPD patients.
• To evaluate the association of FN3K gene variants with cardiorespiratory function in COPD.

Main Methods:

• Immunohistochemistry used to examine FN3K protein in lung tissue from COPD and control subjects.
• ELISA assays performed on serum to measure FN3K and AGE levels in COPD patients receiving metformin.
• Genetic analysis of FN3K and FN3K-RP gene variants in the COPD cohort.

Main Results:

• FN3K expression in blood and lung epithelium occurs at high or low levels, irrespective of COPD status.
• Higher FN3K expression observed in control smokers, but not in COPD patients or a COPD animal model.
• Metformin increased systemic FN3K levels in COPD subjects, regardless of their baseline FN3K expression status.
• FN3K polymorphisms showed nominal associations with decreased cardiorespiratory function, but did not reach statistical significance after multi-comparison analysis.

Conclusions:

• The study identifies distinct high and low FN3K expressor groups within the COPD cohort.
• Metformin administration induces FN3K levels, suggesting a potential therapeutic strategy.
• This induction may offer a mechanism to mitigate CVD comorbidity and mortality risk in COPD.